Medicus Pharma LTD

Medicus Pharma Ltd. has mutually agreed with YA II PN, LTD. (Yorkville) to terminate their Standby Equity Purchase Agreement, effective September 11, 2026, with no outstanding borrowings or fees.

Medicus Pharma Ltd. announced the issuance of restricted common shares to officers and employees in lieu of cash bonuses, valued at approximately $1.45 million.

Medicus Pharma Ltd. has entered into a material definitive agreement with Pfizer Inc. to co-develop and license an early clinical-stage antibody-drug conjugate, PF-08046031 (CD228V).

Medicus Pharma Ltd. has entered into a note purchase agreement with Streeterville Capital, LLC, securing $22.86 million through two secured promissory notes to fund clinical development and business initiatives.

Medicus Pharma has increased its at-the-market equity offering program to $50 million while disclosing a Nasdaq minimum bid price deficiency notice.

Medicus Pharma Ltd. completed multiple unregistered sales of common shares to YA II PN, Ltd. under a Standby Equity Purchase Agreement, raising approximately $3.8 million.

Medicus Pharma Ltd. filed its Q2 2026 Form 10-Q, detailing increased operating expenses, substantial net losses, and a warning about its ability to continue as a going concern, though clinical trial progress was noted.

Medicus Pharma Ltd. reported a significant increase in net loss for Q1 2026, driven by higher operating expenses, while advancing its clinical pipeline and completing strategic acquisitions.

Medicus Pharma Ltd. reported a significantly increased net loss for Q3 2025, driven by higher R&D expenses including the Antev acquisition, while raising substantial capital through equity and debt.

Medicus Pharma Ltd. reported a significant increase in net loss for Q2 2025, driven by higher R&D and administrative costs, while actively pursuing strategic acquisitions and multiple capital raises.

Medicus Pharma reports a net loss for Q1 2025 while advancing its clinical trial for SkinJect and securing additional financing through a Regulation A offering and a Standby Equity Purchase Agreement.

Medicus Pharma Ltd. has filed an amendment to its 2025 Form 10-K, primarily to include previously omitted Part III information regarding directors, executive compensation, and corporate governance.

Medicus Pharma Ltd. announced positive Phase 2 clinical trial results for its D-MNA skin cancer treatment and provided updates on its Teverelix program and financing activities, despite ongoing operating losses and a going concern warning.

Medicus Pharma Ltd. files an amendment to its annual report on Form 10-K to include information required by Part III, covering directors, executive officers, corporate governance, and executive compensation.

Medicus Pharma Ltd. outlines the terms and conditions of its common and preferred shares, as well as outstanding public and 2030 warrants, in its recent Form 10-K filing.

Andrew Alasdair Smith, Chief Operating Officer of Medicus Pharma Ltd., reported multiple transactions in common stock on September 4, 2026.

Faisal Mehmud, Chief Medical Officer of Medicus Pharma Ltd., reported multiple transactions in common stock on September 4, 2026.

Edward J. Brennan, Chief Scientific Officer of Medicus Pharma Ltd., reported multiple transactions in common stock on September 4, 2026.

Carolyn F. Bonner, President and CFO of Medicus Pharma Ltd., reported multiple transactions in common stock on September 4, 2026.

Raza Bokhari, Chief Executive Officer and a Director of Medicus Pharma Ltd., reported multiple transactions in common stock on September 4, 2026.

Medicus Pharma Ltd. Chief Operating Officer Andrew Alasdair Smith was granted 200,000 stock options exercisable at $0.36 per share.

Medicus Pharma Ltd. is convening its Annual General and Special Meeting to seek shareholder approval for critical corporate governance amendments, auditor changes, and a significant dilutive equity financing agreement, while facing a 'going concern' uncertainty and disclosed material weaknesses in internal controls.

Medicus Pharma Ltd. files S-1 for the resale of up to 2.68 million common shares by a selling shareholder, highlighting ongoing clinical trials and significant financial losses.

Medicus Pharma Ltd. filed an S-1 registration statement for the resale of up to 1,397,184 common shares by selling shareholders following its acquisition of Antev Limited and its Teverelix drug candidate.

Medicus Pharma Ltd. details ongoing clinical trials for SkinJectTM and Teverelix, recent capital raises, and significant operating losses, raising going concern doubts.

Medicus Pharma Ltd., a clinical-stage biotech company, has filed an S-1 registration statement for a public offering of up to 1,375,000 units, aiming to raise approximately $10 million to fund its Phase 2 clinical trials for basal cell carcinoma and support general corporate purposes, despite ongoing operating losses and a 'going concern' warning from its auditor.

Medicus Pharma Ltd., a clinical-stage biotech company, has filed an S-1 registration statement to allow for the resale of up to 3.71 million common shares by a selling shareholder, while also disclosing significant operating losses, a going concern warning, and updates on its lead skin cancer drug candidate and a new acquisition.

Dr. Raza Bokhari, CEO of Medicus Pharma Ltd., has disclosed beneficial ownership of approximately 5.3% of the company's common shares through direct holdings and an investment entity.

Ajay Raju and associated entities report a combined 3.7% beneficial ownership in Medicus Pharma Ltd. common shares.

Dr. Raza Bokhari and RBx Capital, LP have disclosed a combined beneficial ownership of 4.8% of Medicus Pharma Ltd.'s common shares.

Armistice Capital, LLC and Steven Boyd have disclosed a passive 4.99% beneficial ownership stake in Medicus Pharma Ltd., totaling 935,724 common shares as of June 30, 2025.

Dr. Kenneth Melani and Velocity Fund Partners, LP report beneficial ownership of Medicus Pharma shares exceeding 15%.

John Hathaway and SkinJect Partners LLC report a 4.5% passive ownership stake in Medicus Pharma Ltd. through a Schedule 13G amendment.

Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a passive beneficial ownership of 9.43% in Medicus Pharma Ltd., totaling 1,266,000 common shares.